Rafael Holdings shares fall after Niemann-Pick trial fails significance
Rafael Holdings’ Trappsol Cyclo did not show a statistically significant slowdown in disease progression in a recent trial, and the stock fell 35% to $1.31.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.